KRAS and leukoencephalopathy with calcifications and cysts: In the present study, both LCC and non-LCC patients under the 2015 WHO criteria presented a high incidence of TP53 (50% vs 93.75%, respectively) and KRAS (25% vs 43.75%, respectively) mutations (Figure 2).